EPISODE · Oct 3, 2022 · 7 MIN
Lecanemab: Alzheimer's, press releases and relative risk
from Pharmacy Microteaches · host Dave Abbott
Lecanemab is the shiny new medicine for Alzheimer's that's been in the press - a 27% decrease in progression sounds great, plus it's a 'mab, so it must be cool. But how might it work, what do we actually know from the press release, and what do we need to have a closer look at?
What this episode covers
Lecanemab is the shiny new medicine for Alzheimer's that's been in the press - a 27% decrease in progression sounds great, plus it's a 'mab, so it must be cool. But how might it work, what do we actually know from the press release, and what do we need to have a closer look at?
NOW PLAYING
Lecanemab: Alzheimer's, press releases and relative risk
No transcript for this episode yet
Similar Episodes
Jun 11, 2026 ·72m
Jun 10, 2026 ·8m
Jun 10, 2026 ·5m
Jun 9, 2026 ·120m